CRISPR Therapeutics Anticipates 2026 Milestones
CRISPR Therapeutics highlighted its strategic priorities and anticipated 2026 milestones. "Entering 2026, CRISPR Therapeutics is well positioned, with CASGEVY gaining momentum, and multiple programs with encouraging data advancing rapidly through clinical trials across a diverse set of therapeutic areas," said Samarth Kulkarni, Ph.D., Chairman and CEO. CRISPR Therapeutics anticipates several key milestones across its portfolio: Continued global commercialization and adoption of CASGEVY, with ongoing quarterly updates. Global regulatory submissions for CASGEVY in patients ages 5 - 11 are expected to be initiated by Vertex in the first half of 2026. Updates from CTX310 are expected in the second half of 2026. Updates from the Lp(a) program are expected in 2026. Top-line Phase 2 clinical data from CTX611 in patients undergoing total knee arthroplasty are expected in the second half of 2026. Updates across autoimmune disease and immuno-oncology for zugocabtagene geleucel are expected in the second half of 2026. The company expects to initiate a clinical trial for CTX460 in alpha-1 antitrypsin deficiency in mid-2026. The company expects to initiate a clinical trial for CTX340 in refractory hypertension in the first half of 2026.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on CRSP
About CRSP
About the author
Wall Street Focuses on Earnings and Commodity Prices
- Earnings Impact: Meta's strong sales forecast and $100 billion AI investment plan drove its stock up in after-hours trading, while Microsoft fell due to slowing cloud growth and soft margin guidance, indicating a divergence in market sentiment towards tech stocks.
- Commodity Market Fluctuations: Gold prices nearing $5600 and silver surpassing $120 reflect investors' demand for safe-haven assets amid economic uncertainty, simultaneously boosting trading volumes in related ETFs like GLD and SLV.
- Market Sentiment: Despite Nasdaq and S&P 500 futures rising by 0.4% and 0.3% respectively, retail sentiment towards SPY and QQQ remains extremely bearish, suggesting ongoing investor concerns about market outlook.
- Upcoming Earnings Reports: Investors are keenly awaiting Apple's earnings report, particularly for insights on iPhone demand and AI roadmap updates, while Western Digital and SanDisk are also set to report today, potentially impacting the data storage sector.
CRISPR Therapeutics Faces Renewed Pressure Amid Insider Sales
- Insider Selling Impact: CEO Samarth Kulkarni sold over 90,000 shares over three days last week, unsettling investors despite retaining approximately 85,000 shares, leading to a stock price drop of over 10%.
- Weak Revenue Growth: The company reported only $890,000 in revenue for Q3, significantly below the consensus estimate of $8.06 million, which further eroded investor confidence and negatively impacted stock performance.
- Momentum Score Decline: CRISPR's momentum score in Benzinga's stock rankings fell from 76.81 to 50.97, indicating poor price trends and volatility across multiple time frames, reflecting unfavorable short- and medium-term price movements.
- Fund Holding Changes: Frequently featured in Cathie Wood's funds, CRISPR's declining momentum score may lead to reduced confidence among investors, potentially affecting its holdings in these funds.
